Can sarcopenia predict complete response after total neoadjuvant therapy in advanced rectal cancer? A multicentre observational cohort study
Journal of Surgical Oncology · 2023
DOI: 10.1002/jso.27251 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Surgical Oncology, 2023. Verfasst von Sergei Bedrikovetski und 6 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Surgery, Faculty of Health and Medical Sciences, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia. Hauptthemen laut MEDLINE: Sarcopenia, Hypoalbuminemia, Rectal Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of Adelaide.
Abstract (Originalsprache)
Background
The association between sarcopenia and response to neoadjuvant treatment remains unclear. This study investigates sarcopenia as a predictor of overall complete response (oCR) after Total Neoadjuvant Therapy (TNT) for advanced rectal cancer.
Method
A prospective observational study was performed of patients with rectal cancer undergoing TNT at three South Australian hospitals between 2019 and 2022. Sarcopenia was diagnosed by pretreatment computed tomography measurement of psoas muscle cross‐sectional area at the third lumbar vertebra level, normalised for patient height. The primary endpoint was oCR rate defined as the proportion of patients who achieved either clinical complete response (cCR) or pathological complete response.
Results
This study included 118 rectal cancer patients with an average age of 59.5 years, 83 (70.3%) of whom formed the non‐sarcopenic group (NSG) and 35 (29.7%) the sarcopenic group (SG). The oCR rate was significantly higher in NSG compared with the SG ( p < 0.001). cCR rate was significantly greater in NSG compared with the SG ( p = 0.001). Multivariate analysis revealed sarcopenia ( p = 0.029) and hypoalbuminemia ( p = 0.040) were risk factors for cCR and sarcopenia was an independent risk factor for oCR ( p = 0.020).
Conclusion
Sarcopenia and hypoalbuminemia were negatively associated with tumour response following TNT in advanced rectal cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Discipline of Surgery, Faculty of Health and Medical Sciences, School of Medicine, University of Adelaide, Adelaide, South Australia, Australia.
- Colorectal Unit, Department of Surgery, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Department of Medical Oncology, The Queen Elizabeth Hospital, Adelaide, South Australia, Australia.
- Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
- Department of Medical Oncology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Förderung
- University of Adelaide
Zitieren
APA
Bedrikovetski, S., Traeger, L., Price, T. J., Carruthers, S., Selva-Nayagam, S., Moore, J. W., & Sammour, T. (2023). Can sarcopenia predict complete response after total neoadjuvant therapy in advanced rectal cancer? A multicentre observational cohort study. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27251
Vancouver
Bedrikovetski S, Traeger L, Price TJ, Carruthers S, Selva-Nayagam S, Moore JW, et al. Can sarcopenia predict complete response after total neoadjuvant therapy in advanced rectal cancer? A multicentre observational cohort study. Journal of Surgical Oncology. 2023. doi:10.1002/jso.27251
BibTeX
@article{Bedrikovetski2023,
author = {Bedrikovetski, Sergei and Traeger, Luke and Price, Timothy J and Carruthers, Scott and Selva-Nayagam, Sudarshan and Moore, James W and Sammour, Tarik},
title = {Can sarcopenia predict complete response after total neoadjuvant therapy in advanced rectal cancer? A multicentre observational cohort study},
journal = {Journal of Surgical Oncology},
year = {2023},
doi = {10.1002/jso.27251}
}
EUVIMED